Calithera Biosciences (CALA) – Investment Analysts’ Weekly Ratings Updates

Calithera Biosciences (NASDAQ: CALA) has recently received a number of price target changes and ratings updates:

  • 12/4/2019 – Calithera Biosciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/27/2019 – Calithera Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
  • 11/19/2019 – Calithera Biosciences was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 11/19/2019 – Calithera Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $7.00 price target on the stock.
  • 11/18/2019 – Calithera Biosciences was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “
  • 11/11/2019 – Calithera Biosciences was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “
  • 11/11/2019 – Calithera Biosciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.

Calithera Biosciences stock traded down $0.11 during trading on Tuesday, hitting $4.49. 319,723 shares of the company were exchanged, compared to its average volume of 309,331. The company has a market capitalization of $241.45 million, a P/E ratio of -3.01 and a beta of 2.02. The business’s 50 day moving average is $3.69 and its 200 day moving average is $4.00. Calithera Biosciences Inc has a 52 week low of $2.45 and a 52 week high of $6.90. The company has a current ratio of 7.39, a quick ratio of 7.39 and a debt-to-equity ratio of 0.06.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. Equities analysts expect that Calithera Biosciences Inc will post -1.92 EPS for the current year.

In related news, major shareholder Bvf Partners L. P/Il purchased 1,598,977 shares of Calithera Biosciences stock in a transaction that occurred on Tuesday, October 29th. The stock was bought at an average price of $2.60 per share, for a total transaction of $4,157,340.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Value Fund L. P. Biotechnology purchased 88,253 shares of Calithera Biosciences stock in a transaction that occurred on Thursday, November 14th. The shares were bought at an average price of $4.30 per share, with a total value of $379,487.90. Over the last ninety days, insiders bought 4,404,157 shares of company stock valued at $13,700,668. 17.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in CALA. BlackRock Inc. grew its position in shares of Calithera Biosciences by 5.8% during the 2nd quarter. BlackRock Inc. now owns 3,228,764 shares of the biotechnology company’s stock valued at $12,593,000 after acquiring an additional 175,625 shares during the period. Vanguard Group Inc. grew its holdings in Calithera Biosciences by 32.3% during the second quarter. Vanguard Group Inc. now owns 2,113,189 shares of the biotechnology company’s stock valued at $8,242,000 after purchasing an additional 515,969 shares during the period. Point72 Asset Management L.P. bought a new position in Calithera Biosciences during the second quarter valued at $7,550,000. CVI Holdings LLC bought a new position in Calithera Biosciences during the second quarter valued at $3,289,000. Finally, Renaissance Technologies LLC increased its position in Calithera Biosciences by 53.0% in the second quarter. Renaissance Technologies LLC now owns 750,198 shares of the biotechnology company’s stock worth $2,926,000 after buying an additional 260,000 shares during the last quarter. 65.88% of the stock is currently owned by institutional investors and hedge funds.

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.